本报时报记者 卢梦雪 见习记者 张萌 北京报道 6月4日晚，港股上市的宜宾市商业银行（下称"宜宾银行"）发布公告，宣布董事会审议通过委任蒋琳为该行行 长，并建议其担任执行董事。 这项任命终结了宜宾银行近两个月的行长空缺期。原行长杨兴旺因"个人身体原因"于今年4月8日突然辞职，而彼 时距离宜宾银行登陆港交所还未满三个月。 新任行长蒋琳的履历丰富，从政府公职人员到五粮液集团高管，再到银行掌舵者，跨越政、企、金融三大领域。 2023年9月起，蒋琳开始担任宜宾银行非执行董事，同时继续兼任五粮液集团的相关职务。履新的背后，这家新晋 港股银行面临的挑战依旧显著：2024年营业收入增速骤降至0.5%，净息差缩窄至1.71%，制造业贷款不良率大幅 攀升……蒋琳的接任能否带领宜宾银行突破增长瓶颈，仍需时间检验。 新行长就任 曾拟任副行长但未获批准 行长之位空缺近两个月后，46岁的蒋琳经宜宾银行董事会审议通过，被委任为行长，并建议担任执行董事。 早在2023年9月，宜宾市人民政府便提名蒋琳担任宜宾银行副行长、董事职务，同时免去其在五粮液集团的副总经 理、董事职务。然而，蒋琳的副行长任职资格始终未获得监管部门的核准。同月，国家金融 ...

Core Viewpoint - The controversy surrounding the product "Kefumei" from Giant Biological has intensified, with the company defending its product's integrity against allegations of false advertising and insufficient collagen content [1][2]. Company Overview - Giant Biological, established in 2000, went public on the Hong Kong Stock Exchange in 2022 and specializes in skin care products featuring recombinant collagen as a key active ingredient [2]. - The company owns several brands, with "Kefumei" and "Kelin" being its core products [2]. Financial Performance - In 2024, Giant Biological reported revenue of 5.539 billion yuan, a year-on-year increase of 57.17%, and a net profit attributable to shareholders of 2.062 billion yuan, up 42.06% [2]. - The "Kefumei" brand generated revenue of 4.542 billion yuan in 2024, reflecting a 62.9% year-on-year growth, increasing its share of the company's total revenue from 79.1% to 82% [2]. Industry Context - The recombinant collagen industry is experiencing growth, while the hyaluronic acid sector, represented by Huaxi Biological, is facing challenges, including declining revenue and profits [2][3]. - Huaxi Biological reported a revenue drop of 4.45% in 2023, with a further decline of 11.61% in 2024, alongside a significant decrease in net profit [3]. Market Reaction - Following the controversy, Giant Biological's stock price fell by 8.70% to 60.85 HKD per share, with a total market value of approximately 65.165 billion HKD, and a cumulative decline of 25.20% over nine trading days [3].

碧桂园第三次延长境外债务重组支持协议同意费期限，希望年内完成境外债务重组 金十数据6月6日讯，碧桂园（02007.HK）发布公告，根据境外债务重组支持协议，继续延长重组支持 协议同意费用限期，这是碧桂园第三次延长同意费用期限。公告称，公司可酌情单方面延长早鸟重组支 持协议同意费用限期和一般重组支持协议同意费用限期。有众多债权人尚未加入重组支持协议，但彼等 支持建议重组。该等债权人正在办理其常规内部审批程序，办理后方可正式加入重组支持协议。碧桂园 的境外债务重组涉及债务的本金额为140.74亿美元。今年以来，碧桂园有意加快重组的进展，并希望能 在2025年12月31日前完成。 （澎湃） ...

港股药品股短线拉升，石药集团(01093.HK)涨超11%，泰凌医药(01011.HK)涨超4%，石四药集团 (02005.HK)涨超3%，翰森制药(03692.HK)涨超2%。 ...

港股创新药概念股午后拉升，石药集团涨超10%，绿叶制药、信达生物、中国生物制药、诺诚健华纷纷 拉升。 无需港股通，A股账户就能T+0买港股>> ...

金十数据6月6日讯，"中国海油"微信公众号消息，6月6日，中国海洋石油集团有限公司召开中层以上管 理人员大会。中央组织部有关负责同志宣布了中央关于中国海洋石油集团有限公司董事长、党组书记任 职的决定：张传江同志任中国海洋石油集团有限公司董事长、党组书记，免去其中国大唐集团有限公司 董事、总经理、党组副书记职务。相关职务任免按有关法律和章程的规定办理。 张传江任中国海洋石油集团有限公司董事长、党组书记 ...

Group 1 - The core viewpoint of the report maintains the Non-IFRS net profit forecasts for 2025 and 2026 for the company, with a current price corresponding to 20.1x and 17.5x Non-IFRS P/E for those years, respectively [1] - The company has a target price of HKD 36, which corresponds to 25x and 21x Non-IFRS P/E for 2025 and 2026, indicating a potential upside of 21.4% [1] - Recent market interest in the IP economy has led the company to enhance its IP industry chain by acquiring a 26.67% stake in Yihua Kaitian [1] Group 2 - The company's IP derivative business is expected to accelerate, with a projected GMV of over RMB 500 million in 2024, including over RMB 200 million from card products [2] - The company has opened 8 offline stores in major cities and is expanding its sales network through distribution channels [2] - The company plans to focus on lightweight peripheral products and aims to enhance both GMV and profitability through its rich IP resources and a youthful team [2] Group 3 - The company has a rich reserve of projects from Xinli Media, including several series and films planned for 2025 and 2026 [3] - The expected profit for Xinli Media in 2025 is projected to be RMB 380 million, with online business expected to remain relatively stable [3] Group 4 - The company announced the acquisition of a 26.67% stake in Yihua Kaitian for a total consideration of RMB 325 million, increasing its ownership to 31.48% [4] - Yihua Kaitian specializes in animation and game development, with projected pre-tax losses of RMB 61 million and RMB 224 million for 2023 and 2024, respectively [4] - The acquisition is expected to enhance the company's capabilities across the entire IP value chain, from incubation to commercialization [4]

Core Insights - The 11th A-TECH Conference, hosted by Times Angel, focused on early orthodontic treatment solutions, efficient management of complex cases, and the integration of digital and AI technologies in orthodontics [1][3][15] - The conference showcased Times Angel's latest advancements in medical thinking, product development, and technology implementation, emphasizing the importance of innovation in the orthodontic field [1][15] Group 1: Innovations and Product Launches - Times Angel launched the A10 expansion solution, addressing the common issue of maxillary transverse deficiency in children, with over 30% of Chinese children affected [6][10] - The company introduced the AngelMind invisible orthodontic system, which integrates biological principles and treatment methodologies, reflecting a deep understanding of medical essence [5][6] - The new "Angel Activator HG" headgear combines traditional principles with invisible treatment systems, enhancing treatment efficiency and patient compliance for Class II high-angle cases [6][10] Group 2: Advanced Technologies - Times Angel unveiled the "Angel Locking Guide" and "Angel Curved Guide" to tackle complex orthodontic challenges, improving treatment efficiency and patient comfort [7][9] - The iOrtho2025 platform was introduced, focusing on enhancing clinical efficiency and patient communication through AI-driven decision support [11][13] - The AngelScanner A8, a lightweight and efficient oral scanner, was launched, integrating seamlessly with the iOrtho platform to streamline operations and improve communication [14] Group 3: Expert Insights and Collaboration - Experts at the conference highlighted the transformative impact of AI on traditional orthodontic practices, emphasizing the need for continuous innovation [3][5] - The event featured case studies and discussions on complex treatment strategies, showcasing the collaborative efforts of global orthodontic professionals [10][15] - Times Angel aims to build a more efficient, precise, and intelligent digital orthodontic ecosystem in partnership with global dental professionals [5][15]

新华财经上海6月6日电（记者王淑娟）6日，友邦保险宣布其独立非执行主席及独立非执行董事谢仕荣 将退任，自2025年9月30日起生效，而杜嘉祺将"回归"接任。不久前，汇丰控股宣布杜嘉祺将于9月30日 退任汇丰集团主席及董事会。 此次杜嘉祺"回归"友邦备受市场瞩目。杜嘉祺曾于2010年至2017年间担任友邦保险集团首席执行官兼总 裁，2017年出任汇丰集团主席至今。 （文章来源：新华财经） 谢仕荣表示："杜嘉祺在担任友邦保险集团首席执行官兼总裁期间，对友邦保险的卓越贡献重大且深 远。他的经验及专长，包括曾担任集团首席执行官，以及近年来出任全球最大金融机构之一的集团主 席，将确保友邦保险能够受益于其卓越的领导。" 友邦保险集团首席执行官兼总裁李源祥表示："杜嘉祺为友邦保险作为一家全球领先的独立上市集团奠 定了基础。多年来，杜嘉祺在国际上的卓著声誉日益提升。我们期望受益于他在金融服务领域的丰富经 验，以及他对亚洲的热忱，带领董事会迈步向前。" 友邦保险是专注于亚洲的独立上市人寿保险集团，友邦保险今日的业务成就可追溯至1919年逾一个世纪 前于上海的发源地。截至2024年年末，友邦保险总资产值为3050亿美元。此外，友 ...

Core Viewpoint - The 2025 ASCO Annual Meeting will showcase significant research achievements of domestic innovative drugs, highlighting their potential in oncology treatment [1] Group 1: Innovative Drug Highlights - Several innovative drug molecules with first-in-class or best-in-class potential will present data, including IBI363 from Innovent Biologics, SKB264 from Kelun-Biotech, and others [1] - IBI363 is the world's first next-generation IO dual antibody designed with IL 2α bias, showing promising efficacy in treating IO-resistant tumors such as NSCLC, melanoma, and CRC [2] Group 2: Clinical Data and Efficacy - In a Phase I clinical study, IBI363 demonstrated an overall response rate (ORR) of 43.3% and a disease control rate (DCR) of 90.0% in squamous NSCLC patients at a 3 mg/kg dosage, with a median progression-free survival (mPFS) of 7.3 months [2] - For adenocarcinoma patients previously treated with PD-(L)1 therapy, the 3 mg/kg group showed an ORR of 76.0% and a DCR of 90.0%, with an mPFS of 4.2 months [2] Group 3: Comparative Efficacy - IBI363 exhibited significant clinical activity in IO-resistant lung squamous and adenocarcinoma patients, outperforming existing therapies such as docetaxel and various immune combination treatments [3] Group 4: Colorectal Cancer Potential - IBI363 also shows promise in late-line CRC treatment, with clinical studies indicating an overall survival (OS) of 16.1 months for patients treated with IBI363 monotherapy [5][6] - Compared to standard treatments like TAS-102 combined with bevacizumab, IBI363 demonstrated superior survival outcomes in patients with worse baseline characteristics [6]